Objective: To review the available published data concerning the use of sublingual immunotherapy (SLIT) in respiratory allergy to primarily evaluate the clinical efficacy and safety of the treatment and to secondarily consider the mechanisms of action and any unresolved questions.
Data Sources: Articles in the medical literature (starting from 1986 up to November 2003) derived from searching the MEDLINE database with the keywords sublingual immunotherapy, respiratory allergy, asthma, and rhinitis. Sources included review articles, randomized controlled clinical trials, postmarketing surveillance studies, and relevant reports from meeting proceedings.
Study Selection: Articles concerning safety, efficacy, and mechanisms of SLIT published in English-language, peer-reviewed journals.
Results: SLIT proved effective and safe in adults and children. As with traditional subcutaneous immunotherapy, SLIT has long-lasting efficacy and a preventive effect on new sensitizations.
Conclusion: SLIT is a viable alternative to subcutaneous immunotherapy. Its use in pediatric patients seems to be particularly promising.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1081-1206(10)61440-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunoprophylaxis with MV140 Is Effective in the Reduction of Urinary Tract Infections-A Prospective Real-Life Study.
Vaccines (Basel)
December 2024
Urology Department, Hospital de Santa Maria, 1649-028 Lisbon, Portugal.
Background/objectives: Urinary tract infections (UTI) represent a highly frequent and debilitating disease. Immunoactive prophylaxis, such as the polyvalent bacterial whole-cell-based sublingual vaccine MV140, have been developed to avoid antibiotic use. However, the effectiveness of this tool in the Portuguese population is still unknown.
View Article and Find Full Text PDFAdjuvant Effect of in Sublingual Immunotherapy of Asthmatic Mice.
Pharmaceuticals (Basel)
November 2024
Department of Pathogen Biology and Microecology, School of Basic Medical Sciences, Dalian Medical University, Dalian 116044, China.
: Sublingual immunotherapy (SLIT) has shown promise in mitigating allergic asthma symptoms; nevertheless, its high dose and prolonged duration of treatment raise safety concerns. This study explored the potential of () to enhance the effectiveness of SLIT in a mouse model of allergic asthma. : Allergic asthma was induced in Balb/c mice following sensitization and challenge with a house dust mite (HDM) allergen.
View Article and Find Full Text PDFAdvancing paediatric allergy care: key findings from the largest trial of house dust mite sublingual immunotherapy-tablets in children.
Lancet Reg Health Eur
January 2025
COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
[Mechanisms of allergen-specific immunotherapy].
Nihon Yakurigaku Zasshi
January 2025
Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development.
Allergen-specific immunotherapy (AIT) has been a longstanding treatment for allergic diseases. Historically, subcutaneous immunotherapy was the main approach, but with the development of sublingual preparations, which are associated with fewer systemic side effects, sublingual immunotherapy is gaining global popularity. In Japan, the approval of standardized sublingual immunotherapy preparations in 2014 has significantly accelerated its adoption.
View Article and Find Full Text PDF[Clinical efficacy of sublingual immunotherapy for allergic rhinitis].
Nihon Yakurigaku Zasshi
January 2025
Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University.
The prevalence of allergic rhinitis (AR) reached 49.2% in 2019. In particular, the prevalence of Japanese cedar (JC) pollinosis is 38.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!